May, 18 2017 12:36 JST

Source: Eisai

Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting

Results of Study of Lenvima (Lenvatinib) in Hepatocellular Carcinoma to Be Presented in Oral Session

TOKYO, May, 18 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima / Kisplyx, "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven, "eribulin"), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.

Detailed data regarding the results of a Phase III clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.

Major poster presentations will include a highlight of the results of a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and the results of a Phase I clinical trial of H3B-8800 in patients with advanced myeloid malignancies.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
November 20 2017 14:50 JST
 
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
November 20 2017 14:28 JST
 
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
November 06 2017 19:37 JST
 
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
October 31 2017 12:05 JST
 
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
October 31 2017 10:27 JST
 
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
October 24 2017 10:08 JST
 
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
October 13 2017 09:48 JST
 
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
October 11 2017 11:48 JST
 
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
October 04 2017 09:49 JST
 
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan
October 03 2017 14:11 JST
 
More Press release >>

Latest Press Release


More Latest Release >>